In clinical studies in which TYMLOS was administered once daily to postmenopausal women with osteoporosis:Early increases in a bone formation marker peaked at month 11

P1NP* bone formation marker levels were maintained above baseline throughout treatment1

Bone turnover marker levels at peak and at end of study with TYMLOS1

Bone turnover marker levels - p1np-levels

Serum procollagen type 1 N-propeptide.1

Serum collagen type 1 cross-linked C-telopeptide.1

See the abaloparatide
mechanism of action video

Learn More

Reference: 1.TYMLOS® [prescribing information]. Waltham, MA: Radius Health, Inc; 2018.

This site is intended for HCPs in the United States.

All other trademarks are the property of their respective owners.

© 2020 Radius Health, Inc.   All rights reserved.    04/20.   TYM-US-03380

This site is intended for HCPs in the United States.
TYMLOS is a registered trademark of Radius Health, Inc.
All other trademarks are the property of their respective owners.

© 2020 Radius Health, Inc.
All rights reserved. 04/20.
TYM-US-03380

Back to Top